AstraZeneca Announces First Direct-to-Patient Program Offering the Brand ARIMIDEX® (anastrozole) Tablets to Patients for Only $40 Per Month

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced its first-ever direct-to-patient program offering patients with a valid prescription for ARIMIDEX or anastrozole the opportunity to have the brand ARIMIDEX delivered directly to their home by Express Scripts, a specialty pharmacy services provider, for $40 per month, including shipping. “ARIMIDEX Direct marks a first for AstraZeneca,” said Steve Davis, Executive Director, Foundation Brands, AstraZeneca. “We believe it is

Feed Date: 
February 16, 2012